ImageneBio, Inc.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
IMA$3.97-3.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
| September 30,2025 | December 31,2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $103,162 | $12,118 |
| Marketable securities | 39,421 | — |
| Prepaid expenses and other current assets (1) | 4,949 | 350 |
| Total current assets | 147,532 | 12,468 |
| Non-current assets: | ||
| Operating lease right-of-use assets, net | 884 | 547 |
| Promissory note receivable from related party (Note 8) | 7,510 | — |
| Other non-current assets | 4,952 | 1,019 |
| Deferred offering costs | — | 1,888 |
| Total assets | $160,878 | $15,922 |
| Liabilities, Redeemable Convertible Preferred Shares and Stockholders’ Equity (Deficit) | ||
| Current liabilities: | ||
| Accounts payable | $2,081 | $5,290 |
| Accrued expenses and other current liabilities | 6,902 | 3,460 |
| Deferred revenue, current | — | 650 |
| Lease liabilities, current | 2,161 | 309 |
| Term loan | — | 7,500 |
| Total current liabilities | $11,144 | 17,209 |
| Non-current liabilities: | ||
| Lease liabilities, non-current | 1,284 | 239 |
| CVR liability due to related party (Note 8) | 7,510 | |
| Other non-current liabilities | 1,108 | — |
| Total liabilities | $21,046 | 17,448 |
| Commitments and contingencies (Note 12) | ||
| Redeemable convertible preferred shares: | ||
| Redeemable convertible preferred shares - $0.00005 par value; no shares and 2,905,696 shares authorized as of September 30, 2025 and December 31, 2024, respectively; no shares and 2,163,434 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively; aggregate liquidation preference of $0 and $163,575 as of September 30, 2025 and December 31, 2024, respectively | — | 159,039 |
| Total redeemable convertible preferred shares | — | 159,039 |
| Stockholders’ equity (deficit): | ||
| Series A convertible preferred shares - $0.00005 par value; no shares authorized as of September 30, 2025 and 994,869 shares authorized, issued and outstanding as of December 31, 2024 | — | 18,967 |
| Preferred Stock - $0.001 par value, 10,000,000 shares authorized as of September 30, 2025 and none authorized as of December 31, 2024, respectively; no shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | — | — |
| Voting Common stock - $0.001 par value, 142,000,000 and 57,119,423 shares authorized as of September 30, 2025 and December 31, 2024, respectively; 10,650,956 and 1,409,884 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | 11 | 1 |
| Non-Voting Common Stock - $0.001 par value, 8,000,000 shares authorized as of September 30, 2025 and none authorized as of December 31, 2024, respectively; 530,716 shares and no shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | — | — |
| Additional paid-in capital | 362,870 | 2,158 |
| Accumulated deficit | (223,143) | (179,900) |
| Accumulated other comprehensive income (loss) | 94 | (1,791) |
| Total stockholders’ equity (deficit) | 139,832 | (160,565) |
| Total liabilities, redeemable convertible preferred shares and stockholders’ equity (deficit) | $160,878 | $15,922 |
(1)Includes related party amount of $0.8 million andzero at September 30, 2025 and December 31, 2024, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.